Ilyang Pharmaceutical Co.,Ltd (KO:007575) — Market Cap & Net Worth
Market Cap & Net Worth: Ilyang Pharmaceutical Co.,Ltd (007575)
Ilyang Pharmaceutical Co.,Ltd (KO:007575) has a market capitalization of $92.33 Million (₩136.24 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19573 globally and #993 in its home market, demonstrating a -2.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilyang Pharmaceutical Co.,Ltd's stock price ₩7500.00 by its total outstanding shares 18165500 (18.17 Million). Also see Ilyang Pharmaceutical Co.,Ltd total assets for a full breakdown of the balance sheet.
Ilyang Pharmaceutical Co.,Ltd Market Cap History: 2015 to 2026
Ilyang Pharmaceutical Co.,Ltd's market capitalization history from 2015 to 2026. Data shows change from $393.13 Million to $92.33 Million (-13.22% CAGR). Also see Ilyang Pharmaceutical Co.,Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Ilyang Pharmaceutical Co.,Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilyang Pharmaceutical Co.,Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ilyang Pharmaceutical Co.,Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Ilyang Pharmaceutical Co.,Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Ilyang Pharmaceutical Co.,Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $302.17 Million | $261.61 Billion | $5.91 Billion | 0.00x | 0.05x |
| 2017 | $306.96 Million | $269.81 Billion | $6.26 Billion | 0.00x | 0.05x |
| 2018 | $220.03 Million | $300.04 Billion | -$4.89 Billion | 0.00x | N/A |
| 2019 | $209.15 Million | $324.57 Billion | $9.98 Billion | 0.00x | 0.02x |
| 2020 | $969.09 Million | $343.33 Billion | $10.88 Billion | 0.00x | 0.09x |
| 2021 | $351.08 Million | $371.35 Billion | $14.38 Billion | 0.00x | 0.02x |
| 2022 | $259.75 Million | $383.81 Billion | $19.24 Billion | 0.00x | 0.01x |
| 2023 | $203.62 Million | $266.67 Billion | -$2.41 Billion | 0.00x | N/A |
| 2024 | $127.78 Million | $268.68 Billion | $9.03 Billion | 0.00x | 0.01x |
| 2025 | $159.79 Million | $272.42 Billion | $6.90 Billion | 0.00x | 0.02x |
Competitor Companies of 007575 by Market Capitalization
Companies near Ilyang Pharmaceutical Co.,Ltd in the global market cap rankings as of September 18, 2026. Review 007575 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ilyang Pharmaceutical Co.,Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Ilyang Pharmaceutical Co.,Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Ilyang Pharmaceutical Co.,Ltd's market cap moved from $393.13 Million to $ 92.33 Million, with a yearly change of -13.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩92.33 Million | -42.22% |
| 2025 | ₩159.79 Million | +25.05% |
| 2024 | ₩127.78 Million | -37.24% |
| 2023 | ₩203.62 Million | -21.61% |
| 2022 | ₩259.75 Million | -26.01% |
| 2021 | ₩351.08 Million | -63.77% |
| 2020 | ₩969.09 Million | +363.34% |
| 2019 | ₩209.15 Million | -4.94% |
| 2018 | ₩220.03 Million | -28.32% |
| 2017 | ₩306.96 Million | +1.59% |
| 2016 | ₩302.17 Million | -23.14% |
| 2015 | ₩393.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Ilyang Pharmaceutical Co.,Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $92.33 Million USD |
| MoneyControl | $92.33 Million USD |
| MarketWatch | $92.33 Million USD |
| marketcap.company | $92.33 Million USD |
| Reuters | $92.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more